TGF-β and regulation of interstitial nephritis

Mineral and Electrolyte Metabolism

Volumn 24, Issue 2-3, 1998, Pages 181-189

  Frishberg, Yaacov ^a   Kelly, Carolyn J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Immunoregulation; Interstitial nephritis; Kidney disease; T lymphocytes; TGF

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; PRIORITY JOURNAL; REVIEW;

ANIMALS; CELL DIVISION; GROWTH INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEPHRITIS, INTERSTITIAL; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031908022     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057368     Document Type: Review

References (47)

1. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990;346: 371-374.
2. Barnes J, Abboud H: Temporal expression of autocrine growth factors correspond to morphological features of mesangial proliferation in Habu snake venom-induced glomerulonephritis. Am J Phathol 1993;143:1366-1376.
3. Jones C, Buch S, Post M, McCulloch L, Liu E, Eddy A: Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis. Am J Pathol 1992;141:1381-1396.
4. Kaneto H, Morrissey J, Klahr S: Increased expression of TGF-beta 1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 1993;44:313-321.
5. Sharma K, Ziyadeh F: Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am J Physiol 1994;267:F1094-F1101.
6. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA: Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90:1814-1818.
7. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi YU, Pierschbacher MD, Ruoslahti E: Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992;360: 361-364.
8. Akagi Y, Isaka Y, Arai M, Kaneko T, Takenaka M, Moriyama T, Kaneda Y, Ando A, Orita Y, Kamada T, Ueda N, Imai E: Inhibition of TGF-bl expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996;50:148-155.
9. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E: Glomerulosclerosis by in vivo transfection of transforming growth factor beta and platelet-derived growth factor gene into the rat kidney. J Clin Invest 1993;92:2597-2601.
10. Kagami S, Border W, Miller D, Noble N: Angiotensin II stimulated extracellular matrix protein synthesis through induction of transforming growth factor beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93:2431-2437.
11. Shihab F, Andoh T, Tanner A, Noble N, Border W, Franceschini N, Bennett W: Role transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy. Kidney Int 1996;49:1141-1151.
12. Yamamoto T, Noble N, Cohen A, Nast C, Hishida A, Gold L, Border W: Expression of transforming growth factor-beta isoforms in human glomerular disease. Kidney Int 1996; 49:461-469.
13. Yoshioka K, Takemura T, Murakami K, Okada M, Hino S, Miyamoto H, Maki S: Transforming growth factor beta protein and mRNA in glomeruli in normal and diseased human kidneys. Lab Invest 1993;68:154-163.
14. Shihab F, Yamamoto T, Nast C, Cohen A, Noble N, Gold L, Border W: Transforming growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts. J Am Soc Nephrol 1995;6:286-294.
15. Shull M, Ormsby I, Kier A, Pawlowski S, Diebold R, Yin M, Allen R, Sidman C, Proetze G, Calvin D: Target disruption of the mouse transforming growth factor-beta one gene results in multifocal inflammatory disease. Nature 1992;359:693-699.
16. Letterio J, Geiser A, Kulkarni A, Dang H, Kong L, Nakabayashi T, Mackall C, Gress R, Roberts A: Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression. J Clin Invest 1996;98:2109-2129.
17. Kelly CJ, Roth DA, Meyers CM: Immune recognition and response to the renal interstitium. Kidney Int 1991;39:518-531.
18. Meyers CM, Kelly CJ: Effector mechanisms in organ-specific autoimmunity. I. Characterization of a CD8+ T cell line that mediates murine interstitial nephritis. J Clin Invest 1991;88: 408-416.
19. Nielson EG, Gasser DL, McCafferty E, Zakheim B, Phillips SM: Polymorphism of genes involved in anti-tubular basement membrane disease in rats. Immunogenetics 1983;17:555-565.
20. Neilson EG, Phillips SM: Murine interstitial nephritis. I. Analysis of disease susceptibility and its relationship to pleiomorphic gene products defining both immune-response genes and a restrictive requirement for cytotoxic T cells at H-2k. J Exp Med 1982;155:1075-1085.
21. Neilson EG, McCafferty E, Mann R, Michaud L, Clayman M: Murine interstitial nephritis. III. The selection of phenotypic (Lyt and L3T4) and idiotypic (RE-Id) T cell preferences by genes in Igh-1 and H-2K characterize the cellmediated potential for disease expression: Susceptible mice provide a unique effector T cell repertoire in response to tubular antigen. J Immunol 1985;134:2375-2382.
22. + regulatory T cells. J Immunol 1987;136:4200-4208.
23. Kelly CJ, Mok H, Neilson EG: The selection of effector T cell phenotype by contrasuppression modulates susceptibility to autoimmune injury. J Immunol 1988;141:3022-3028.
24. + suppressor T cells which are antigen spe-cific and inhibit the expression of disease. J Immunol 1986;136:903-907.
25. Neilson EG, McCafferty E, Mann R, Michaud L, Clayman M: Tubular antigen derivatized cells induce a disease protective, antigen-specific, and idiotype-specific suppressor T cell network restricted by IJ and Igh-V in mice with experimental interstitial nephritis. J Exp Med 1985;162:215-230.
26. Neilson EG, Kelly CJ, Clayman MD, Mines WH, Haverty T, Sun MJ, Blanchard N: Murine interstitial nephritis. VII. Suppression of renal injury after treatment with soluble suppressor factors TsF1. J Immunol 1987;139:1518-1524.
27. Kelly CJ, Tomaszewski JE, Neilson EG: Immunopathogenesis of tubulointerstitial injury; in Brenner BM, Tisher CC (ed): Renal Pathology, ed 2. Philadelphia, Lippincott, 1993, pp699-722.
28. Meyers CM, Kelly CJ: Inhibition of murine nephritogenic effector T cells by a clone-specific suppressor factor. J Clin Invest 1994;94: 2093-2104.
29. Li B, Sehajpal P, Khanna A, Vlassara H, Cerami A, Stenzel K, Suthanthiran M: Differential regulation of transforming growth factor B and interleukin 2 genes in human T cells: Demonstration by usage of novel competitor DNA constructs in the quantitative polymerase chain reaction. J Exp Med 1991;174:1259-1262.
30. Frishberg Y, Meyers CM, Kelly CJ: Cyclosporine A regulates T cell-epithelial cell adhesion by altering LFA-1 and ICAM-1 expression. Kidney Int 1996;50:45-53.
31. Meyers CM, Kelly CJ: Immunoregulation and TGF-betal: Suppression of a nephritogenic murine T cell clone. Kidney Int 1994;46:1295-1301.
32. Brandes A, Allen J, Ogawa Y, Wahl S: Transforming growth factor beta one suppresses acute and chronic arthritis in experimental animals. J Clin Invest 1991;87:1108-1113.
33. Racke M, Dhib-Jalbut S, Cannella B, Albert P, Raine C, McFarlin D: Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta. J Immunol 1991;146:3012-3017.
34. Santambrogio L, Hochwald G, Saxena B, Leu C, Martz J, Carlino J, Ruddle N, Palladino M, Gold L, Thorbecke G: Studies on the mechanisms by which transforming growth factorbeta protects against allergic encephalomyelitis: Antagonism between TGF-beta and tumor necrosis factor. J Immunol 1993;151:1116-1127.
35. Johns L, Sriram S: Experimental allergic encephalomyelitis: Neutralizing antibody to TGF beta 1 enhances the clinical severity of the disease. J Neuroimmunol 1993;47:1-7.
36. Miller A, Al-Sabbagh A, Santos L, Das M, Weiner H: Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. J Immunol 1993;151:7307-7315.
37. Khoury S, Hancock W, Weiner H: Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 1992;176:1355-1364.
38. Meyers CM, Kopp JB, Klotman P, Kelly CJ: Renal antigen-specific T cell clones elicit distinct patterns of interstitial injury and TGF-beta expression. J Am Soc Nephrol 1992;3: 604.
39. Bailey NC, Frishberg Y, Kelly CJ: Loss of high affinity TGF-betal binding to a nephritogenic T cell results in absence of growth inhibition by TGF-betal and augmented nephritogenicity. J Immunol 1996;156:3009-3016.
40. Bailey N, Schwartz I, Kelly C: A point mutation in the transmembrane domain of a type I transforming growth factor receptor abolishes growth arrest of murine proximal tubular cells by TGF-beta. J Am Soc Nephrol 1996;7:1692.
41. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Willson JKV: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatelIite instability. Science 1995;268:1336-1338.
42. Wang J, Sun L, Myeroff L, Wang X, Gentry LE, Yang J, Liang J, Zborowska E, Markowitz S, Willson JKV, Brattain MG: Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication errorpositive colon carcinoma cells. J Biol Chem 1995;270:122044-22049.
43. Neilson EG, Sun MJ, Emery J, Kelly CJ, Haverty T, Clayman M, Cooke NE: Molecular characterization of a major nephritogenic domain in the auto-antigen of anti-tubular basement membrane disease. Proc Natl Acad Sci USA1991;88:2006-2010.
44. Sporn M, Roberts A: Peptide growth factors are multifunctional. Nature 1988;332:217-219.
45. Kitamura M, Burton S, English J, Kawachi H, Fine L: Transfer of a mutated gene encoding active transforming growth factor-beta 1 suppresses mitogenesis and IL-1 response in the glomerulus. Kidney Int 1995;48:1747-1757.
46. Kitamura M, Suto T, Yokoo T, Shimizu F, Fine L: Transforming growth factor-beta 1 is the predominant paracrine inhibitor of macrophage cytokine synthesis produced by glomerular mesangial cells. J Immunol 1996;156:2964-2971.
47. Suto T, Fine L, Kitamura M: Mesangial cellderived transforming growth factor-beta 1 reduces macrophage adhesiveness with consequent deactivation. Kidney Int 1996;50:445-452.